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taken in account when OCT data are interpretated.3,4 
Does this clinically silent demyelination mirror disease 
activity, and thus correspond with parameters such as 
brain and spinal cord atrophy and expanded disability 
severity score (EDSS), or is it also responsible for OCT 
results that do not correlate with the clinical course?5 
The assumption that clinically silent demyelination 
mirrors disease activity provides a more plausible 
explanation for the correlation between retinal 
thickness and disability than does the hypothesis of 
trans-synaptic retrograde neurodegeneration.6,7 These 
questions are important for the interpretation of OCT 
ﬁ ndings and for their use as surrogate markers for 
neurodegeneration and risk of disability worsening.2,5,8,9 
They might be answered in future by carefully planned 
prospective studies with reproducible serial OCT 
measurements recorded at short intervals over longer 
periods. In the meantime, we do not see the utility of 
monitoring pRNFL thickness by OCT for the prediction 
of the likelihood of disability worsening. 
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Chromosomal deletion at 22q11.2 and Parkinson’s disease
Chromosome 22q11.2 deletion syndrome is a group of 
heterogeneous disorders characterised by a deletion 
near the middle of chromosome 22 at a location 
designated q11.2. The clinical phenotype varies widely, 
with multiple system involvement. Well-recognised 
features include cleft palate, dysmorphic facial features, 
cardiac defects, skeletal deformities, developmental 
delays, and learning disabilities.1 Many aﬀ ected people 
are identiﬁ ed at a young age. These patients are at an 
increased risk of developing schizophrenia and other 
mental disorders, and have a reduced lifespan.
Despite the multiple system involvement, an 
association between 22q11.2 deletion syndrome 
and Parkinson’s disease was not suspected until 
the publication of independent case reports of co-
occurrence of parkinsonism in patients with 22q11.2 
deletion syndrome.2,3 Interest in this possible link 
increased after Butcher and colleagues4 reported four 
patients with early-onset Parkinson’s disease in their 
study of 159 adults with 22q11.2 deletion syndrome. 
They found that the use of antipsychotics in these 
patients delayed diagnosis of Parkinson’s disease by 
up to a decade and typical Lewy bodies were present in 
two of three patients at post mortem. All of the nine 
reported cases with 22q11.2 deletion syndrome in the 
published work so far had age at onset of Parkinson’s 
disease of younger than 50 years.4–6
In The Lancet Neurology, Kin Mok and colleagues5 
examined the opposite association; that is, they looked 
for deletions at 22q11.2 in four independent case-
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control Parkinson’s disease d atasets from diﬀ erent 
European populations. They did array-based copy 
number variation analyses of data from 9387 patients 
with Parkinson’s disease and 13 863 controls. 
They found a signiﬁ cant increase of the common 
3 Mb deletion (associated with 22q11.2 deletion 
syndrome) in Parkinson’s disease (eight cases) 
compared with controls (no cases; p=0·00082). The 
deletions were associated with disease age at onset, 
with 0·49% frequency in patients with early-onset 
Parkinson’s disease (<45 years) compared with 0·04% 
frequency in those with an age of onset of 45 years 
or older (p=0·005). These ﬁ ndings corroborate those 
from previous case reports2,3 and provide further 
support for an association between 22q11.2 deletion 
syndrome and Parkinson’s disease, especially in 
patients with early-onset disease. Although an 
association does not prove causality, it provides 
impetus to look for a novel Parkinson’s disease gene 
within the deleted region.
Missense mutations of pathogenic genes have 
been well described in Parkinson’s disease.6,7 
Additionally, copy number variants involving 
recessive (eg, PARKIN, PINK1) and dominant genes 
(SNCA) have also been implicated in familial 
Parkinson’s disease. Whether haploinsuﬃ  ciency of a 
single gene or a group of genes in the 22q11.2 region 
is responsible for the development of Parkinson’s 
disease remains unknown. This could be investigated 
by knocking down individual genes or studying the 
eﬀ ect of deletion mutants in neuronal cultures. 
Further validation in animal models (ie, gene 
knockdown) could be done to verify dopaminergic 
neuronal loss and other pathological features of 
Parkinson’s disease. Deep sequencing of genes in the 
remaining hemizygous allele to identify mutations 
might identify novel recessive causative genes, 
although this might be challenging since these 
patients generally do not have a positive family 
history (most are carriers of de-novo mutations). 
A combination of a deletion and a mutation in the 
opposite allele or with other epigenetic factors is 
another possibility. Some of the candidate genes 
within this region (eg, COMT, DGCR8, and SEPT5) 
are possible causative genes because of their 
interaction with known Parkinson’s disease genes or 
dopaminergic pathways. 
Although Mok and colleagues highlight the possible 
clinical eﬀ ects (eg, screening and genetic counselling) 
of their ﬁ ndings, we should approach their ﬁ ndings 
with cautious optimism. First, both the estimated 
prevalence of 22q11.2 deletion syndrome in the general 
population (0·024%) and that of a 22q deletion among 
patients with early-onset Parkinson’s disease (0·49%) 
are low. Hence, any large-scale eﬀ ect on screening in the 
general population of patients with Parkinson’s disease 
will be small. Second, including the present study, the 
number of patients identiﬁ ed with coexistent 22q11.2 
deletion syndrome and Parkinson’s disease is still low 
(<20). Phenotype characterisation of these patients is 
still scarce. Three of the six cases in the present study 
had previous psychiatric or cognitive problems, but 
these diagnoses seemed to be based on historical 
information, and comprehensive neuropsychological 
testing, systematic screening, and details regarding 
treatment complications were not available. Third, we do 
not know why only 3% of patients with 22q11.2 deletion 
syndrome develop Parkinson’s disease6 and whether 
there are any speciﬁ c clinically useful warning signs and 
factors that might aﬀ ect penetrance in patients who 
might develop parkinsonian symptoms subsequently. 
Despite many missing connections in the patho-
physiological link between 22q11.2 deletion syndrome 
and Parkinson’s disease, the present study will certainly 
raise clinicians’ awareness and heighten their vigilance 
in looking for features of 22q11.2 deletion syndrome in 
patients with early-onset Parkinson’s disease, and carefully 
considering Parkinson’s disease as a diﬀ erential diagnosis 
in patients with 22q11.2 deletion syndrome even if these 
patients are on antipsychotic drugs. Further functional 
experiments, replication studies in independent clinical 
cohorts, and identiﬁ cation of additional cases with 
chromosomal deletion sizes other than the 3 Mb region 
will shed more light on this interesting association. 
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Treating neurodegenerative disease before illness: 
a challenge for the 21st century
Clinicians have long recognised that pathological 
processes can impair organ function before clinical signs 
emerge, especially in chronic illness. Cardiac myocytes 
and renal tubular epithelial cells are thought to dwindle 
well in advance of overt clinical signs of cardiac and 
renal failure. Furthermore, often in retrospect, patients 
recognise that non-speciﬁ c or subtle symptoms and 
signs (eg, fatigue) occurred before more overt features 
of illness such as pedal oedema or dyspnoea. Evidence 
that elevated systolic blood pressure, serum glucose, 
and cholesterol concentrations are clinically silent—but 
readily measurable—risks for serious illnesses (stroke, 
blindness, renal failure, etc) has led to treatments that 
have strikingly reduced the burden of chronic illnesses. 
The discovery of biomarkers for HIV infection (viral load 
or CD4 cell count) fuelled the development of therapies 
that transformed an acutely lethal illness into one 
with a manageable clinical course. These experiences 
have led many investigators to think that devastating 
neurodegenerative diseases might also be treatable 
before any overt signs of illness arise; David Salat and 
colleagues1 propose such a concept for Parkinson’s 
disease in The Lancet Neurology. This notion is fuelled by 
an increasing understanding of pathological processes 
and improved insight into clinical phenomena that, 
although non-speciﬁ c, might herald or actually represent 
the active neurodegenerative process in Parkinson’s 
disease (eg, constipation or rapid eye movement sleep 
disorder). Such hope, however, should be tempered by 
present research constraints. 
Parkinson’s disease is usually sporadic, although 
some important genetic cohorts are now recognised. 
In autosomal-dominant disorders such as Huntington’s 
disease and dominantly inherited Alzheimer’s disease, 
there is certainty about risk of illness, but uncertainty 
about its timing. By contrast, in idiopathic illnesses 
such as sporadic Parkinson’s disease, we have to rely on 
non-speciﬁ c preclinical markers such as constipation 
to predict disease risk. This reliance is confounded by 
the fact that only a minority of prodromal Parkinson’s 
disease patients have constipation, and the majority of 
individuals with constipation will never have Parkinson’s 
disease. Sorting of the population into a more reﬁ ned 
risk cohort (as Salat and colleagues propose) will require 
greater reﬁ nement of additional biomarkers, whether 
biological ﬂ uid or neuroimaging based. Exposure of 
individuals to treatment for prevention of an illness that 
they are not destined to develop is not justiﬁ able, and 
hence clarity on disease deﬁ nition is essential.
Establishing adequate outcomes in clinical trials is an 
additional challenge. The best outcome would be that 
nothing happens (ie, that illness never emerges). This 
scenario presents some diﬃ  culties, because no disease 
will also be the outcome if researchers mistakenly identify 
and recruit into trials a group not truly at risk. Moreover, 
disease onset is an outcome that can take long follow-up 
periods to observe. Many research participants might be 
reluctant to continue in long studies, on treatment, with 
no hope of improvement (because they are well to begin 
with) and few interim rewards (such as low cholesterol 
concentrations or glycosylated haemoglobin score) for 
continued participation. Furthermore, participation itself 
might stigmatise participants, or remind them of their 
risk status and perceived poor level of health compared 
with their peers.
The assessment of disease onset also presents 
methodological challenges; previous masked studies of 
at-risk cohorts in Huntington’s disease have reported 
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